Novartis Corporation

Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court [Press Release]
PRNewswire | 37 days 3 hours 16 minutes ago
Novartis Pharmaceuticals Corporation Prevails in Medicaid...jury verdict against Novartis Pharmaceuticals Corporation (NPC), and directed...North America, CEO, Novartis Pharmaceuticals Corporation. "NPC is committed...

Novartis drug Tasigna(R) meets primary endpoint in pivotal trial against Gleevec(R) as first-line treatment in chronic myeloid leukemia patients [Press Release]
PRNewswire | 33 days 20 hours 42 minutes ago
EAST HANOVER, N.J., Oct. 20 /PRNewswire/ -- Novartis announced today that Tasigna(R) (nilotinib) 200 mg capsules met its primary endpoint in the first head-to-head comparison with the company's groundbreaking drug Gleevec(R) (imatinib mesylate) tablets*. Tasigna produced faster and deeper responses than Gleevec when given as first-line therapy for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. Tasigna was well tolerate...

Novartis Champions Renewable Energy With New Vacaville Solar Array [Press Release]
Business Wire | 25 days 15 hours 57 minutes ago
Novartis announced today the completion of the new 1 megawatt (MW) solar array near its Vacaville biopharmaceutical site. The announcement was made at a ceremony which celebrated the collective effort of state and local officials, employees and business partners in championing the approval, construction and completion of the $7 million dollar power plant. The five acre array will supply 20% of the manufacturing facility’s electrical needs.

Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia [Press Release]
PRNewswire | 41 days 3 hours 56 minutes ago
...North America, CEO, Novartis Pharmaceuticals Corporation. "With the launch...or otherwise. Novartis Pharmaceuticals Corporation researches, develops...Hanover, New Jersey, Novartis Pharmaceuticals Corporation is an affiliate of...

Newly Published Phase III Data Show Novartis Drug Sandostatin(R) LAR Depot Reduced Risk of Disease Progression by 66% in Advanced NET Patients [Press Release]
PRNewswire | 52 days 19 hours 24 minutes ago
EAST HANOVER, N.J., Oct. 1 /PRNewswire/ -- Data published in the

Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure [Press Release]
PRNewswire | 66 days 10 hours 25 minutes ago
...or otherwise. Novartis Pharmaceuticals Corporation researches, develops...Hanover, New Jersey, Novartis Pharmaceuticals Corporation is an affiliate of...Christine Cascio,Novartis Pharmaceuticals Corporation, Direct +1-862...

Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure [Press Release]
PRNewswire | 66 days 10 hours 25 minutes ago
...or otherwise. Novartis Pharmaceuticals Corporation researches, develops...Hanover, New Jersey, Novartis Pharmaceuticals Corporation is an affiliate of...novartis.com, both of Novartis Pharmaceuticals Corporation; orNovartis Investor...

Results In 'The New England Journal Of Medicine' Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery [Press Release]
PRNewswire | 95 days 9 hours 26 minutes ago
...Located in East Hanover, New Jersey, Novartis Pharmaceuticals Corporation is an affiliate of Novartis AG which provides...Investors only: Megan Humphrey Richard Jarvis Novartis Oncology Novartis Corporation P: +1 862 778 6724 P: +1 212 830 2433...

US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease [Press Release]
PRNewswire | 98 days 1 hour 26 minutes ago
EAST HANOVER, N.J., Aug. 17 /PRNewswire/ -- The US Food and Drug Administration (FDA) has approved Extavia(R) (interferon beta-1b), the first in a new planned portfolio of multiple sclerosis (MS) medicines from Novartis to help patients manage this devastating disease.

Nielsen Announces 2009 Winners of the First-Ever CLIO Healthcare Awards [Press Release]
PRNewswire | 6 days 7 hours 55 minutes ago
... Chandler Chicco Agency, Strategic Communications/Public Relations, Direct to Professional, Novartis Pharmaceuticals Corporation, "The Christopher Film Series" American Academy of Orthopaedic Surgeons, Strategic Communications...

Research and Markets: Hepatitis C Virus and Therapeutics Report - A Global Update of Market Trends & Opportunities [Press Release]
Business Wire | 3 days 13 hours 37 minutes ago
Research and Markets (http://www.researchandmarkets.com/research/f6bf5e/hepatitis_c_virus) has announced the addition of the "Hepatitis C Virus And Therapeutics - A Global Update of Market Trends & Opportunities" report to their offering.

Amylin Pharmaceuticals Board of Directors Elects Paulo F. Costa Chairman of the Board [Press Release]
PRNewswire | 90 days 18 hours 56 minutes ago
...President and Chief Executive Officer of Novartis U.S. Corporation, where he held several other executive...President and Chief Executive Officer of Novartis Pharmaceutical Corporation. Prior to joining Novartis, Mr. Costa worked at Johnson & Johnson...

Research and Markets: Asia-Pacific Drug Delivery Devices Report - Investment Opportunities, Analysis and Forecasts to 2015 [Press Release]
Business Wire | 40 days 2 hours 7 minutes ago
Research and Markets (http://www.researchandmarkets.com/research/25f111/asiapacific_drug) has announced the addition of Global Markets Direct's new report "Asia-Pacific Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2015" to their offering.

Research and Markets: South and Central America Drug Delivery Devices Report - Investment Opportunities, Analysis and Forecasts to 2015 [Press Release]
Business Wire | 40 days 16 hours 57 minutes ago
Research and Markets (http://www.researchandmarkets.com/research/1f7019/south_and_central) has announced the addition of Global Markets Direct's new report "South and Central America Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2015" to their offering.

Research and Markets: North America Drug Delivery Devices Investment Opportunities, Analysis and Forecasts Through to 2015 [Press Release]
Business Wire | 40 days 14 hours 47 minutes ago
Research and Markets (http://www.researchandmarkets.com/research/373a36/north_america_drug) has announced the addition of Global Markets Direct's new report "North America Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2015" to their offering. This report is an essential source for in-depth information and data relating to North America drug delivery devices market. It also offers detailed and comprehensive coverage of market revenue, volume, distribution and compan...